Arcellx Raises $115m To Advance Novel T-Cell Therapies
First CAR-T In Phase I, Second Construct Heading For Clinic
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.
You may also be interested in...
Biotech stock indices have seen a recent recovery but remain well below their 2021 peaks raising questions about the likelihood of raising money for R&D. The number of companies announcing leadership changes, shifting pipeline priorities and job cuts is rising as a result.
Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.
New board directors named at Eli Lilly, Immunicum, and Talaris Therapeutics.